2022
DOI: 10.1038/s41568-022-00536-4
|View full text |Cite
|
Sign up to set email alerts
|

Biology, vulnerabilities and clinical applications of circulating tumour cells

Abstract: In recent years, exceptional technological advances have enabled the identification and interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading to new fields of research and fostering the promise for paradigm-changing, liquid biopsy-based clinical applications. Analysis of CTCs has revealed distinct biological phenotypes, including the presence of CTC clusters and the interaction between CTCs and immune or stromal cells, impacting metastasis formation and providing new ins… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
77
0
1

Year Published

2023
2023
2024
2024

Publication Types

Select...
6
3
1

Relationship

1
9

Authors

Journals

citations
Cited by 103 publications
(78 citation statements)
references
References 249 publications
0
77
0
1
Order By: Relevance
“…Tumor metastasis is the primary reason for more than 90% of cancer-associated deaths. In the process of tumor metastasis, circulating tumor cells (CTCs) are shed from the solid tumors and enter the bloodstream, eventually colonizing in distant tissues or organs and forming new metastatic foci. CTCs have been regarded as important noninvasive biomarkers and hold great potential for early cancer diagnosis, prediction of recurrence, and individualized treatment. However, the extremely rare CTCs are present in the complex whole blood, which contains only a few to a dozen CTCs per mL while billions of blood cells. Some materials have been developed to improve the capture performance toward CTCs, while most of them cannot achieve fully stereo contacts with target cells. Compared with the smooth plane, the three-dimensional (3D) micro-/nanostructure with the ability to interact with cells can significantly improve the capture efficiency of CTCs . In addition, the fragility of CTCs is another key issue that needs to be considered.…”
Section: Introductionmentioning
confidence: 99%
“…Tumor metastasis is the primary reason for more than 90% of cancer-associated deaths. In the process of tumor metastasis, circulating tumor cells (CTCs) are shed from the solid tumors and enter the bloodstream, eventually colonizing in distant tissues or organs and forming new metastatic foci. CTCs have been regarded as important noninvasive biomarkers and hold great potential for early cancer diagnosis, prediction of recurrence, and individualized treatment. However, the extremely rare CTCs are present in the complex whole blood, which contains only a few to a dozen CTCs per mL while billions of blood cells. Some materials have been developed to improve the capture performance toward CTCs, while most of them cannot achieve fully stereo contacts with target cells. Compared with the smooth plane, the three-dimensional (3D) micro-/nanostructure with the ability to interact with cells can significantly improve the capture efficiency of CTCs . In addition, the fragility of CTCs is another key issue that needs to be considered.…”
Section: Introductionmentioning
confidence: 99%
“…After entry into the bloodstream, CTCs (known as inherent metastatic factors) can infiltrate healthy tissues that are distant from the tumour [11]. Nevertheless, CTC clusters display metastatic potential of 20-to 100-fold greater metastatic potential than single CTCs [12][13][14]. Other possible targets of migrastatic agents are mechanisms of cell mobility (e.g., cytoskeletal dynamics and cell contractility) and energy provisions (e.g., ATP availability, mitochondrial metabolism) [15].…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, many details remain unclear as it is almost impossible to predict when and where metastases emerge in vivo. Thus we are often limited to study metastasis via circulating tumor cells, biopsies, and postmortem analysis of metastases 17,18 .…”
Section: Introductionmentioning
confidence: 99%